Insider Selling: Sotera Health (NASDAQ:SHC) Director Sells 9,720,000 Shares of Stock

Sotera Health Company (NASDAQ:SHC) Director Pincus & Co. Warburg sold 9,720,000 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $16.33, for a total value of $158,727,600.00. Following the completion of the sale, the director directly owned 34,102,952 shares of the company’s stock, valued at $556,901,206.16. The trade was a 22.18% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Pincus & Co. Warburg also recently made the following trade(s):

• On Monday, November 10th, Pincus & Co. Warburg sold 18,000,000 shares of Sotera Health stock. The stock was sold at an average price of $15.65, for a total transaction of $281,700,000.00.

Sotera Health Stock Performance

Shares of NASDAQ SHC traded up $0.19 during midday trading on Friday, reaching $16.75. 3,411,098 shares of the company traded hands, compared to its average volume of 3,307,954. The company has a market cap of $4.76 billion, a price-to-earnings ratio of 88.16 and a beta of 1.81. The stock has a 50-day moving average price of $16.29 and a 200 day moving average price of $14.32. Sotera Health Company has a 52 week low of $9.53 and a 52 week high of $17.78. The company has a debt-to-equity ratio of 4.04, a current ratio of 2.38 and a quick ratio of 2.18.

Sotera Health (NASDAQ:SHC) last announced its quarterly earnings data on Tuesday, November 4th. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.04. Sotera Health had a net margin of 4.82% and a return on equity of 43.69%. The company had revenue of $311.31 million for the quarter, compared to analysts’ expectations of $303.63 million. Sotera Health has set its FY 2025 guidance at 0.810-0.860 EPS. Sell-side analysts anticipate that Sotera Health Company will post 0.61 earnings per share for the current fiscal year.

Institutional Trading of Sotera Health

Hedge funds have recently modified their holdings of the stock. Farther Finance Advisors LLC grew its position in Sotera Health by 55.9% during the 2nd quarter. Farther Finance Advisors LLC now owns 9,861 shares of the company’s stock worth $110,000 after acquiring an additional 3,534 shares during the last quarter. Strs Ohio bought a new stake in shares of Sotera Health during the first quarter worth about $1,003,000. Public Employees Retirement System of Ohio increased its stake in shares of Sotera Health by 4.0% in the second quarter. Public Employees Retirement System of Ohio now owns 48,635 shares of the company’s stock valued at $541,000 after buying an additional 1,891 shares during the period. Two Seas Capital LP raised its holdings in Sotera Health by 21.1% in the 2nd quarter. Two Seas Capital LP now owns 4,020,867 shares of the company’s stock valued at $44,712,000 after buying an additional 699,731 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its position in Sotera Health by 5.1% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,415,282 shares of the company’s stock worth $16,502,000 after buying an additional 68,087 shares during the period. Institutional investors and hedge funds own 91.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Barclays raised their target price on shares of Sotera Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “hold (c-)” rating on shares of Sotera Health in a report on Tuesday. BMO Capital Markets initiated coverage on shares of Sotera Health in a research note on Thursday, November 13th. They issued an “outperform” rating and a $19.00 price target for the company. Piper Sandler lifted their price objective on shares of Sotera Health from $15.00 to $17.00 and gave the company a “neutral” rating in a research report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. upped their target price on shares of Sotera Health from $14.00 to $16.00 and gave the company a “neutral” rating in a report on Wednesday, November 5th. Three investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, Sotera Health has an average rating of “Moderate Buy” and an average price target of $17.80.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.